Associated Genetic Biomarkers
HIST1H3C is altered in 0.60% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, squamous cell lung carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in HIST1H3C are HIST1H3C Amplification (0.11%), HIST1H3C Loss (0.07%), HIST1H3C E98K (0.01%), HIST1H3C E106K (0.01%), and HIST1H3C R130C (0.01%) .
HIST1H3C status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains HIST1H3C status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with HIST1H3C status in the inclusion eligibility criteria most commonly target diffuse midline glioma, H3 K27M-mutant .
The most frequent alteration to serve as an inclusion eligibility criterion is HIST1H3C K28M .
H3k27m peptide vaccine, atezolizumab, imiquimod, and radiation therapy are the most frequent therapies in trials with HIST1H3C as an inclusion criteria .
Significance of HIST1H3C in Diseases
Diffuse Midline Glioma, H3 K27M-Mutant +
HIST1H3C is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains HIST1H3C status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.